Medison Ventures

The firm leverages its parent company's experience in multi-country drug commercialization to evaluate portfolio companies on more than just scientific merit. Medison Pharma has built a track record of bringing therapies from global innovators like Biogen into markets that those companies cannot reach directly. This gives the venture team operational-grade diligence capabilities when assessing a startup's regulatory strategy, reimbursement pathway, and eventual commercial launch challenges.

The Medison-Pontifax Venture Debt Fund is a joint vehicle created in partnership with Pontifax, a prominent life sciences investment firm specializing in credit strategies. The fund provides non-dilutive structured debt to biotechnology and therapeutics companies, typically at late preclinical through clinical-stage. This partnership combines Medison's pharmaceutical operating expertise with Pontifax's established debt-platform infrastructure and track record.

While the firm has a primary geographic focus on Israeli-founded life sciences companies—reflecting the country's density of drug development innovation—Medison Ventures also evaluates opportunities in North America and Europe. The investment lens prioritizes firms where the parent entity's commercialization network or regulatory expertise can add strategic value beyond capital.

Medison Ventures functions as a hybrid entity: it represents the investment arm of Medison Pharma, with capital originating from pharmaceutical operations rather than a family office structure. The firm operates with the flexibility of a corporate venture group but without a single industrial parent's strategic mandate constraints. The team makes direct equity investments in addition to managing the co-managed venture debt fund.

Founder Meir Jakobsohn, who serves as Executive Chairman of both Medison Pharma and Medison Ventures, anchors the investment function. The firm operates with a lean team model, drawing on the broader Medison Pharma executive network for technical and commercial diligence. Specific day-to-day investment committee composition has not been publicly disclosed.